CTOs on the Move


 
Medly Pharmacy is a full-service, digital pharmacy that delivers your prescription medication to you for free, same day, anywhere in New York City and New Jersey. We created a digital experience that makes managing your prescription simple, efficient, and smart for patients and providers.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.medly.com
  • 104 Graham Avenue
    Brooklyn, NY USA 11206
  • Phone: 718.782.7539

Executives

Name Title Contact Details
Prasad Pola
Chief Technology Officer Profile

Funding

Medly raised $100M on 07/14/2020

Similar Companies

GeNOsys

GeNOsys (generated nitric oxide systems) Inc. is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.

Onco360 Pharmacy

Onco360 provides industry-leading Oncology Pharmacy services for Patients, Physicians, Pharma, Payers, & Hospitals. Learn more.